ELAN Stock — Elanco Animal Health Inc

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 8 wks

Latest filing: 10-Q

filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$5.02B

Trailing 12 months

Net income (TTM)

−$199.00M

Trailing 12 months

Revenue growth YoY

+10.2%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

3.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.2%

Year over year · more shares

Price change (1Y)

+25.8%

Trailing year

Short interest

5.9%

Latest settlement · 2.5 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026

Q2 FY26

TL;DR. Elanco reported Q2 organic constant currency revenue growth of 8% and raised full-year guidance, including innovation revenue to ~$1.25 billion, adjusted EBITDA to $1.01–$1.035B, adjusted EPS to $1.10–$1.16, and improved its year-end net leverage target to ~3.0x. Results were driven by 11% growth in U.S. Pet Health and U.S. Farm Animal, led by Zenrelia and Credelio Quattro.

Bullish

+ Reported 8% organic constant currency revenue growth and 11% growth in both U.S. Pet Health and U.S. Farm Animal, outperforming high end of guidance.
+ Raised full-year adjusted EBITDA guidance to $1.01–$1.035B (13% growth at midpoint) and adjusted EPS to $1.10–$1.16 (20% growth at midpoint).
+ Adjusted EBITDA grew 21% and adjusted EPS grew 31% year-over-year, with adjusted gross margin up 80 basis points.
+ Improved year-end net leverage target to approximately 3.0x from prior 3.0–3.2x range, with net debt down ~$90M in the quarter.
+ Zenrelia reached blockbuster status with U.S. JAK share up 9 points YoY and Credelio Quattro added 4 points of broad-spectrum share in Q2, reaching over 50% of U.S. clinics.

Bearish

− Reported net interest expense increased $11M YoY to $59M, partly from imputed interest on sale-of-future-revenue liability.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Neutral Sentiment Very Bullish Fundamentals Fair Quant / Vol Moderate

Market backdrop VIX 15.7 · calm Equity put/call 0.48

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −1%

below

Price vs 50-day avg −4%

below

RSI (14) 44

neutral

MACD trend Negative

52-week position 61%

mid-range

Volume (OBV) Bearish div.

distributing

Momentum

relative strength

Neutral

1-month return +4%

trailing

6-month return −5%

trailing

YTD return +4%

this year

Relative strength −20%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) No cross

50d $25 › 200d $24 — 50d above 200d

Institutional flow Accumulating

+0% holders QoQ · +79 funds added

Insider flow Accumulating

Net +$1.5M over 90 days · 0% sells

Short interest Falling

5.95% of float · ▼ -17.5% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

521 holders — near 3-yr high, broad support

Squeeze score 55

elevated · 0–100

Fundamentals

Fair

Revenue growth +6%

Y/Y

Gross margin 55%

expanding

EPS growth −169%

Y/Y

Free cash flow $284.0M

Balance sheet $3.9B

net debt

Quant / Vol

risk profile

Moderate

Volatility 42%

annualized · 1-yr

Max drawdown −26%

past year

ATR 3.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 3

Latest guidance · from the 8-K filed Aug 5, 2026

2026 full year

Revenue growth (excluding foreign exchange, AHV International ac Non-GAAP Initiated 6% – 7%

Adjusted gross margin Non-GAAP Initiated 55.2% – 55.6%

Revenue tailwind from favorable impact of foreign exchange rates Initiated $60M

2026 Third Quarter

Revenue growth (excluding foreign exchange, AHV International ac Non-GAAP Initiated 5% – 7%

Prior guidance period ended · from the 8-K filed Aug 8, 2024

Innovation revenue · full year 2024 $400M – $450M

Revenue contribution · 2025 $600M – $700M

Adjusted EPS · full year $0.88 – $0.96

Reported net income · Full Year $314M – $352M

Adjusted EBITDA · Full Year $900M – $940M

Adjusted EBITDA margin · Full Year 20.4% – 21.1%

Guided vs delivered · last 3 settled

Total revenue 2021 full year

guided $4.73B – $4.77B

guided $4.73B – $4.77B $4.76B In line

Revenue fourth quarter of 2021

guided $1.08B – $1.12B

guided $1.08B – $1.12B $1.11B In line

Revenue third quarter of 2021

guided $1.08B – $1.1B

guided $1.08B – $1.1B $1.13B Beat +4.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 5 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−1% Neutral

Price vs 50-day avg

−4% Neutral

RSI (14)

44 Neutral

MACD trend

Negative Bearish

52-week position

61% Neutral

Volume (OBV)

Bearish div. Bearish

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) No cross

50d $25 › 200d $24 — 50d above 200d

Institutional flow Accumulating

+0% holders QoQ · +79 funds added

Insider flow Accumulating

Net +$1.5M over 90 days · 0% sells

Short interest Falling

5.95% of float · ▼ -17.5% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

521 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $18 Now $24 · 61% Range high $27

vs 200-day avg -1% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ELAN Elanco Animal Health Inc this stock	$11.98B	+4.1%	+6.2%	—	5.9%
TAK Takeda Pharmaceutical Co Ltd	$58.15B	+16.8%	—	—	0.1%
GALDY Galderma Group AG/ADR	$46.42B	-7.7%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$42.94B	+18.1%	+4.3%	60.4	3.1%
HLN Haleon plc	$40.33B	-8.7%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

521

% held: 113.5%
Net QoQ: +20.6M sh
Top holder: Dodge & Cox

Held Float

View

Held by Funds

Fund positions

503

View

Short & Settlement

Short Interest Falling

Shares short

29.7M

Days to cover: 2.5d
Change: -6.3M sh

View

Short Volume

Short vol %

47%

As of: Sep 9, 2026

Short Total

View

Fails to Deliver

FTD shares

527.6K

Value: $13.5M
As of: Aug 5, 2026

View

Off-Exchange

Off-exchange %

51.2%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Cluster buy

Net (90d)

+$1.5M

Buyers / Sellers: 5 / 0

Buyers Sellers

View

Congressional Trades Sell

Member

Valerie Hoyle

Amount: $1.0K–$15.0K
Traded: Sep 23, 2025

View

Financials

Revenue (FY)

$4.7B

Net income (FY): $-232.0M
EPS diluted: $-0.47

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 10

View

Proposed Sales

Value

$830.0K

Shares: 49.3K
Filed: Aug 11, 2025

View

Earnings & Events

Earnings Calls

Last call

Aug 5, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
ELAN	-1.5%	+3.6%	-5.2%	-1.6%	+4.1%
SPY	+0.1%	-1.1%	+15.3%	-0.6%	+11.8%
vs SPY	-1.6%	+4.7%	-20.4%	-0.9%	-7.7%

ELAN · Elanco Animal Health Inc

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance